Expiration of Valid Claims. On a Licensed Product-by-Licensed Product and Region by Region basis, if at any time during the Royalty Term in a given Region in the Territory, there is no Valid Claim of a Licensed Patent Right Covering a composition of matter (excluding formulation) of such Licensed Product that would be infringed by the sale of such Licensed Product in such Region, then the applicable royalty rate in effect with respect to such Licensed Product in such Region as specified in Section 6.2(a) (Royalty Rate) will be reduced by [***] for the remainder of the Royalty Term for such Licensed Product in such Region.
Expiration of Valid Claims. Subject to Section 9.2.3(d) (Cumulative Reductions Floor), if during the Royalty Term for a given Licensed Product in the United States there is no Valid Claim of a Takeda Patent Right Covering the Exploitation of such Licensed Product (or the Licensed Compound contained therein) in the United States, then, as from the first Calendar Quarter this Section 9.2.3(b) (Expiration of Valid Claims) applies, and thereafter for so long as this Section 9.2.3(b) (Expiration of Valid Claims) applies, the Licensee Royalty will be reduced by [***] for Net Sales in the United States.
Expiration of Valid Claims. Upon expiration of all VALID CLAIMS, LICENSEE’s ROYALTY obligation shall be reduced by 50%.
Expiration of Valid Claims. Subject to Section 3.3.2.5, in the event that, and in such case from and after the date on which, a Product is sold in a country or other jurisdiction and is not Covered by a Valid Claim of a LipimetiX Patent Right or a Product Patent Right claiming the (i) composition of matter of such Product, the royalty rate for such Product shall be reduced by fifty percent (50%).
Expiration of Valid Claims. On a Licensed Product-by-Licensed Product and country-by-country basis, if during the Royalty Term for such Licensed Product in such country, there is no Valid Claim of a Eureka Licensed Patent Right Covering such Licensed Product in such country in the Licensee Territory, then, commencing in the first Calendar Quarter after the date on which this Section 8.4.2 applies and for the remainder of the Royalty Term for such Licensed Product in such country, subject to Section 8.4.4, the royalties payable by Licensee pursuant to Section 8.3 for such Licensed Product in such country will be reduced by [***]%.
Expiration of Valid Claims. Subject to Section 10.3.3(d) (Cumulative Reductions Floor), on a country-by-country or region-by-region basis, as applicable, in the Territory, if during the Royalty Term for the Licensed Product in such country or region in the Territory, there is no Valid Claim of a Royalty Patent Right that Covers a composition of matter (including drug formulation), method of use, or method of Manufacturing of the Licensed Product in such country or region, then, commencing the first Calendar Quarter after the date on which this Section 10.3.3(a) (Expiration of Valid Claims) applies and for all Calendar Quarters thereafter during such Royalty Term in which this Section 10.3.3(a) (Expiration of Valid Claims) applies, then the royalty rates for the Licensed Product set forth in Table 10.3.1 in such country or region under Section 10.3 (Royalty Payments to Kiniksa) will be reduced by [***]%; provided that if a composition of matter, method of use, or method of Manufacturing of the Licensed Product subsequently becomes Covered by a Valid Claim of a Royalty Patent Right in such country or region prior to the expiration of the Royalty Term for the Licensed Product in such country or region, then the royalty rate of the Licensed Product in such country or region will no longer be subject to the aforementioned reduction beginning at the commencement of the first Calendar Quarter after the date on which the relevant patent issues.
Expiration of Valid Claims. Subject to Section 9.6.3 (Cumulative Effect of Ionis Royalty Reductions), on an Ionis Product-by-Ionis Product and country-by- country basis in the Territory, if during the Royalty Term for an Ionis Product in a given country there is no Valid Claim of a Royalty Bearing Patent Right Covering such Ionis Product in such country, then commencing in the first Calendar Quarter after the date on which this Section 9.6.2(a) (Expiration of Valid Claims) applies and for the remainder of the Royalty Term for such Ionis Product in such country, the Annual Net Sales for such Ionis Product in such country will be reduced by [***]% for purposes of calculating the Ionis Royalties owed under Section 9.6.1 (Ionis Royalty Rates).
Expiration of Valid Claims. Subject to Section 10.3.3(c) (Cumulative Reductions Floor), on a Licensed Product-by-Licensed Product and region-by-region basis, if there is no Valid Claim of a Royalty Patent Right that Covers the Licensed Product [****] in such region, then, commencing [****] after the date on which this Section 10.3.3(a) (Expiration of Valid Claims) applies and for all [****] thereafter during which this Section 10.3.3(a) (Expiration of Valid Claims) applies, the applicable royalty rate that would otherwise be owed on such Net Sales of such Licensed Product in such region under Section 10.3.1 (Royalty Payments to Blueprint) will be [****]; provided that if such Licensed Product [****] subsequently becomes Covered by a Valid Claim within the Royalty Patent Rights in such region prior to [****], then the applicable royalty rate that would otherwise be owed on such Net Sales of such Licensed Product in such region will no longer be subject to the aforementioned reduction beginning at [****].
Expiration of Valid Claims. Subject to Section 7.4.8 (Cumulative Reductions Floor), if during the Royalty Term for the Licensed Product on a country-by-country, product-by-product, basis there is no longer a Valid Claim of any (a) LMI Patent Right that Covers on-going Exploitation of the Precursor, Licensed Compound, or Licensed Product by GEHC or LMI in the Field in such country and provides exclusivity for the Precursor, or Licensed Product in such country, (b) GEHC Improvement Patent Right that Covers on-going Exploitation of the Precursor, Licensed Compound, or Licensed Product by GEHC or LMI in the Field in such country ***, or (c) Joint Patent Right that Covers on-going Exploitation of the Precursor, Licensed Compound, or Licensed Product by GEHC or LMI in the Field in such country *** from the first *** this Section 7.4.5 (Expiration of Valid Claims) applies, all Royalties payable to LMI with respect to Net Sales of such Precursor or Licensed Product, as applicable, in such country will automatically be reduced by ***%.
Expiration of Valid Claims. Upon expiration of all VALID CLAIMS, on a LICENSED PATENT-by-LICENSED PATENT and LICENSED PRODUCT-by-LICENSED PRODUCT basis, the applicable royalty rate shall be reduced by 50%.
